RT Journal Article
SR Electronic
T1 Fragile X Syndrome Carrier Screening Using a Nanopore Sequencing Assay
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.23.24310865
DO 10.1101/2024.07.23.24310865
A1 Xia, Zhongmin
A1 Deng, Qiuxiao
A1 Hu, Ping
A1 Gao, Chunliu
A1 Jiang, Yu
A1 Zhou, Yulin
A1 Guo, Qiwei
YR 2024
UL http://medrxiv.org/content/early/2024/07/26/2024.07.23.24310865.abstract
AB BACKGROUND Fragile X syndrome (FXS) is the leading cause of monogenic autism spectrum disorder and inherited intellectual disabilities. Although the value of population-based FXS carrier screening has been acknowledged, appropriate screening methods are urgently required to establish and implement screening programs.METHODS We developed a nanopore sequencing-based assay that includes data analysis software to identify FXS carriers. Reference and clinical samples were used to evaluate the performance of our nanopore sequencing assay. Triplet-primed PCR and PacBio long-read sequencing were used for comparisons.RESULTS Nanopore sequencing identified reference carrier samples with a full range of premutation alleles in single-, 10-, and 100-plex assays, and identified AGG interruptions in an allele-specific manner. Nanopore sequencing revealed no size preference for amplicons containing different length CGG repeat regions. Finally, nanopore sequencing successfully identified three carriers among ten clinical samples for preliminary clinical validation. The observed variation in CGG repeat region size resulted from the base-calling process of nanopore sequencing.CONCLUSIONS Our nanopore sequencing assay is rapid, high-capacity, inexpensive, and easy to perform, thus providing a promising tool and paving the way for population-based FXS carrier screening.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Natural Science Foundation of China [grant numbers 82071662] and the Natural Science Foundation of Xiamen Municipality [grant numbers 3502Z20227141]Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Signed informed consent was obtained from each participant to authorize the use of their genetic data for research purposes. This study was approved by the Research Ethics Committee of Xiamen University.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscriptFXSfragile X syndromeTP-PCRtriplet-primed PCRFMR1fragile X messenger ribonucleoprotein 1